Xpovio (selinexor) — United Healthcare

Initial criteria

• Diagnosis of relapsed or refractory multiple myeloma (RRMM) AND Patient has received at least four prior therapies AND Disease is refractory to both of: two proteasome inhibitors (e.g., bortezomib, carfilzomib), two immunomodulatory agents (e.g., lenalidomide, thalidomide), and an anti-CD38 monoclonal antibody (e.g., daratumumab) AND Used in combination with dexamethasone
• Diagnosis of multiple myeloma AND Patient has received at least one prior therapy AND Used in combination with one of: Velcade (bortezomib) and dexamethasone, Darzalex (daratumumab) and dexamethasone, Kyprolis (carfilzomib) and dexamethasone
• Diagnosis of multiple myeloma AND Patient has received at least 2 prior therapies including an immunomodulatory agent (e.g., lenalidomide, thalidomide) and a proteasome inhibitor (e.g., bortezomib, carfilzomib) AND Patient has demonstrated progression on or within 60 days of completion of last therapy AND Used in combination with Pomalyst (pomalidomide) and dexamethasone

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Xpovio therapy

Approval duration

12 months